Overview
- NHS England halts routine prescription of puberty blockers to minors with gender dysphoria, citing insufficient evidence of safety and effectiveness.
- The new policy limits hormone therapy to clinical trials, with exceptions in exceptional cases, while current patients remain unaffected.
- Puberty blockers, used since the 1960s for conditions like precocious puberty, face scrutiny over long-term effects on cognitive development, fertility, and bone health.
- Research on puberty blockers for gender dysphoria shows potential mental health benefits but is often contested and based on small sample sizes.
- The decision has sparked debate among medical professionals and LGBTQ groups, with concerns over access to gender-affirming care.